These stocks are thousands of times higher than they traded when the market hit its crisis-era low

Since the market bottomed during the financial crisis, the S&P 500 has gained more than 312 percent, but some individual stocks have gained thousands of times over.

CNBC studied the price performance of stocks in the S&P that were publicly traded 10 years ago. In a list of the top 25, the top performing stock was Ulta Beauty, which is up more than 7,100 percent since then. It is followed by ABIOMED and Netflix, both up more than 6,000 percent. Amazon is up 2,700 percent from that 2009 low. All prices are as of Tuesday's close.

The S&P consumer discretionary sector has been the top performer in the decade since March 2009, gaining 598 percent. Second best has been technology, which is up 522 percent. The financial sector, which represented the epicenter of the crisis, has rebounded 422 percent and is third-best performer. Some key stocks in that sector have bounced back sharply.

thank you MMT 😘

Singapore Singapore Latest News, Singapore Singapore Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Markets Right Now: Stocks open higher on trade hopesTHAT IS STILL LOWER THAN THE MARKET WAS OVER A YEAR AGO The Fed Chairman hasn’t woke up yet.... Give it a minute. 😏 Thanks Trump!
Source: ABC - 🏆 471. / 51 Read more »

U.S. stocks open higher on reports that U.S.-China trade deal is nearSell the market when the deal is clinched.
Source: MarketWatch - 🏆 3. / 97 Read more »

Trump reportedly pushing for trade deal with China in hopes of boosting stock marketPresident Donald Trump is pushing hard to strike a trade deal with China with the hopes of lifting stock prices further, Bloomberg News reports. He is day trading the market After the deal equities will get smashed Big mistake,
Source: CNBC - 🏆 12. / 72 Read more »

Cannabis stocks mostly higher after FDA head promises April talks on CBD regulationCannabis stocks were mostly higher Thursday, as investors digested the latest earnings reports from the sector and comments from the head of the U.S. Food and Drug Administration on plans for regulation of CBD. I'm all about $NBEV at 5.00 :)
Source: MarketWatch - 🏆 3. / 97 Read more »